37 reports of this reaction
1.4% of all ARGATROBAN reports
#18 most reported adverse reaction
CEREBRAL HAEMORRHAGE is the #18 most commonly reported adverse reaction for ARGATROBAN, manufactured by Accord Healthcare Inc.. There are 37 FDA adverse event reports linking ARGATROBAN to CEREBRAL HAEMORRHAGE. This represents approximately 1.4% of all 2,692 adverse event reports for this drug.
Patients taking ARGATROBAN who experience cerebral haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CEREBRAL HAEMORRHAGE is a less commonly reported adverse event for ARGATROBAN, but still significant enough to appear in the safety profile.
In addition to cerebral haemorrhage, the following adverse reactions have been reported for ARGATROBAN:
The following drugs have also been linked to cerebral haemorrhage in FDA adverse event reports:
CEREBRAL HAEMORRHAGE has been reported as an adverse event in 37 FDA reports for ARGATROBAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
CEREBRAL HAEMORRHAGE accounts for approximately 1.4% of all adverse event reports for ARGATROBAN, making it a notable side effect.
If you experience cerebral haemorrhage while taking ARGATROBAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.